公开(公告)号：EP0341291A4

公开(公告)日：1990-07-03

申请号：EP89900112

申请日：1988-11-08

Applicant: BAXTER INT

Inventor： BACEHOWSKI DAVID V ,  MIRIPOL JEFFREY E ,  NEEDHAM THOMAS E ,  KARTINOS NICHOLAS J

IPC: A61K9/22 ,  A61M1/02 ,  A61M1/36

CPC classification number: A61M1/3672 ,  A61M1/3673

Abstract: As one administers blood through a conduit (10) into a container (12), the blood is passed in the conduit across the supply of beneficial agent (18), such as anticoagulant, to cause a controlled amount of beneficial agent to enter the passing blood in a manner that is substantially uniform overtime. The beneficial agent (18) is typically in dry form until it enters into contact with the blood. Accordingly, no substantial portion of the blood is exposed to a significantly higher concentration of the beneficial agent than other portions of the blood.

Abstract translation: 当通过导管（10）将血液施用到容器（12）中时，血液在管道中通过有益剂（18）的供应，例如抗凝血剂，以引起受控量的有益剂进入通过 血液的加班时间基本一致。 有益剂（18）通常是干燥形式，直到其与血液接触。 因此，与血液的其他部分相比，没有相当一部分血液暴露于有益剂量的明显更高的浓度。

公开(公告)号：CA1339088C

公开(公告)日：1997-07-29

申请号：CA582994

申请日：1988-11-14

Applicant: BAXTER INT

Inventor： BACEHOWSKI DAVID V ,  MIRIPOL JEFFREY E ,  NEEDHAM THOMAS E ,  KARTINOS NICHOLAS J

IPC: A61K9/22 ,  A61M1/02 ,  A61M1/36

Abstract: As one administers blood through a conduit into a container, the blood is passed in the conduit across the supply of beneficial agent, such as anticoagulant, to cause a controlled amount of beneficial agent to enter the passing blood in a manner that is substantially uniform over time. The beneficial agent is typically in dry form until it enters into contact with the blood. Accordingly, no substantial portion of the blood is exposed to a significantly higher concentration of the beneficial agent than other portions of the blood.

公开(公告)号：AU5233186A

公开(公告)日：1986-07-01

申请号：AU5233186

申请日：1985-11-29

Applicant: BAXTER INT

Inventor： NEEDHAM THOMAS E ,  WRIGHT JEREMY C ,  STEVE PEARSON ,  CHILAMKURTI RAO N ,  KOPP CLINTON V

IPC: A61M5/168 ,  A61M5/14 ,  A61M39/00

Abstract: Apparatus for safe delivery of a beneficial agent to a patient comprising a chamber (98) for the agent through which a fluid passes to the patient and means for controlling the rate of delivery in two alternative modes. In the first mode fluid flow through the chamber is high enough to provide delivery of the agent at a rate independent of the actual fluid flow rate to provide a therapeutic dose of the agent in approximately thirty minutes. In the second mode, the fluid flow rate in the chamber is low enough for rate delivery of the agent to be at least partially dependent on fluid flow rate through the chamber. The control means ensures that a toxic concentration is not delivered to the patient nor develops in the patient's bloodstream. The control means may take various forms.

公开(公告)号：CA1261701A

公开(公告)日：1989-09-26

申请号：CA496681

申请日：1985-12-02

Applicant: BAXTER INT

Inventor： NEEDHAM THOMAS E ,  WRIGHT JEREMY C ,  PEARSON STEVE ,  CHILAMKURTI RAO ,  KOPP CLINTON V

IPC: A61M5/168 ,  A61M5/14 ,  A61M39/00

Abstract: DRUG DELIVERY APPARATUS PREVENTING LOCAL AND SYSTEMIC TOXICITY An apparatus is provided for the safe, passive reconstitution of a drug or other beneficial agent, without requiring manual reconstitution steps. The apparatus includes a housing, preferably having a receptacle "in-line" in an administration set and forming part of an intravenous delivery system, and a cartridge adapted for receiving a beneficial agent or beneficial agent and carrier. The cartridge is plugged into the receptacle to initiate reconstitution of the agent. The apparatus creates first and second delivery modes, in which the delivery rate of the agent to a patient is independent from and dependent upon, respectively, the fluid flow rate through the intravenous delivery system.

公开(公告)号：AU592546B2

公开(公告)日：1990-01-18

申请号：AU5233186

申请日：1985-11-29

Applicant: BAXTER INT

Inventor： NEEDHAM THOMAS E ,  WRIGHT JEREMY C ,  PEARSON STEVE ,  CHILAMKURTI RAO N ,  KOPP CLINTON V

IPC: A61M5/168 ,  A61M5/14 ,  A61M39/00

Abstract: Apparatus for safe delivery of a beneficial agent to a patient comprising a chamber (98) for the agent through which a fluid passes to the patient and means for controlling the rate of delivery in two alternative modes. In the first mode fluid flow through the chamber is high enough to provide delivery of the agent at a rate independent of the actual fluid flow rate to provide a therapeutic dose of the agent in approximately thirty minutes. In the second mode, the fluid flow rate in the chamber is low enough for rate delivery of the agent to be at least partially dependent on fluid flow rate through the chamber. The control means ensures that a toxic concentration is not delivered to the patient nor develops in the patient's bloodstream. The control means may take various forms.